Filtered By:
Specialty: Pharmaceuticals
Management: Marketing
This page shows you your search results in order of date.
Order by Relevance | Date
Total 73 results found since Jan 2013.
Append Medical Raises $4.35M in Initial Closing of Extended Series A Round
Funds will be used to complete the development of and support the First-in-Human Study of the Appligator for the Prevention of Stroke in Atrial Fibrillation Patients
OR YEHUDA, Israel, July 6, 2023 -- (Healthcare Sales & Marketing Network) -- Append M... Devices, Interventional, Cardiology, Venture Capital Append Medical, Appligator, left atrial appendage, Atrial Fibrillation
Source: HSMN NewsFeed - July 6, 2023 Category: Pharmaceuticals Source Type: news
NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104
Phase 1 safety study of NTS-104 is initiated in healthy volunteers
Compound is being developed for stroke and other Central Nervous System (CNS) injuries
ATLANTA, June 1, 2023 -- (Healthcare Sales & Marketing Network) -- NeuroTrauma Sciences, LLC (N... Biopharmaceuticals, Neurology, Drug Delivery NeuroTrauma Sciences, neurosteroid prodrug, stroke
Source: HSMN NewsFeed - June 1, 2023 Category: Pharmaceuticals Source Type: news
Reach Neuro Receives FDA Breakthrough Device Designation for Device to Restore Arm and Hand Movement to Chronic Stroke Patients
Reach Neuro's Avantis device delivers small electrical impulses to the spinal cord to help stroke survivors regain motion and independence
PITTSBURGH, April 10, 2023 -- (Healthcare Sales & Marketing Network) -- Reach Neuro, Inc., a neurotechnology comp... Devices, Neurology, FDA Reach Neuro, Avantis, stroke
Source: HSMN NewsFeed - April 10, 2023 Category: Pharmaceuticals Source Type: news
MicroTransponder Secures CMS Transitional Pass-Through Status and New Technology Add-On Payment for Its Breakthrough Stroke Rehabilitation System, Vivistim
AUSTIN, Texas, Jan. 31, 2023 -- (Healthcare Sales & Marketing Network) -- MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services (CMS) awarded the Vivistim® Paired VNS System transitional pass-through status, expand... Devices, Neurology, Reimbursement MicroTransponder, Vivistim, Stroke
Source: HSMN NewsFeed - January 31, 2023 Category: Pharmaceuticals Source Type: news
Infinity Neuro Receives CE Mark Approval for Their First Device to Treat Stroke
LAKE FOREST, Calif., Jan. 27, 2023 -- (Healthcare Sales & Marketing Network) --Infinity Neuro announced today that its Inspira aspiration catheters received CE Mark approval and are now commercially available in Europe. This is the first offering from Inf... Devices, Interventional, Neurology, Regulatory Infinity Neuro, Inspira aspiration catheter, stroke
Source: HSMN NewsFeed - January 27, 2023 Category: Pharmaceuticals Source Type: news
RapidPulse Raises Additional Funding for Ischemic Stroke Therapies and Notes Promising Results
MIAMI, Sept. 13, 2022 -- (Healthcare Sales & Marketing Network) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bri... Devices, Interventional, Neurology, Venture Capital RapidPulse, Cyclic Aspiration System, stroke
Source: HSMN NewsFeed - September 13, 2022 Category: Pharmaceuticals Source Type: news
MicroTransponder Raises $53M, Appoints New CEO
AUSTIN, Texas, June 20, 2022 -- (Healthcare Sales & Marketing Network) -- MicroTransponder®, Inc. closed an oversubscribed $53 million Series E funding round led by US Venture Partners (USVP), a multi-stage investment firm. GPG Ventures and Exceller H... Devices, Neurology, Personnel, Venture Capital MicroTransponder, Vivistim, stroke
Source: HSMN NewsFeed - June 20, 2022 Category: Pharmaceuticals Source Type: news
Conformal Medical Announces Launch of CONFORM Pivotal Trial
Study to support U.S. FDA approval of the novel CLAAS® implant for left atrial appendage occlusion (LAAO) and stroke prevention
NASHUA, N.H., June 17, 2022 -- (Healthcare Sales & Marketing Network) -- Conformal Medical, Inc., a medical device compa... Devices, Interventional, Cardiology Conformal Medical, CLAAS System, atrial fibrillation, LAAO
Source: HSMN NewsFeed - June 17, 2022 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
MicroTransponder(R) Receives FDA Approval for Breakthrough Device Benefiting Stroke Survivors
The first-of-its-kind Vivistim® Paired Vagus Nerve Stimulation (VNS) System significantly improves upper limb rehabilitation therapy
DALLAS, Aug. 31, 2021 -- (Healthcare Sales & Marketing Network) -- MicroTransponder, Inc. today announced United St... Devices, Neurology, FDA MicroTransponder, Vivistim Paired VNS System, Vagus Nerve Stimulation, stroke
Source: HSMN NewsFeed - August 31, 2021 Category: Pharmaceuticals Source Type: news
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment
FDA Responds to Company's IND #27375 Including Pharmacology, Manufacturing and Clinical Sections
PHOENIX, May 14, 2021 -- (Healthcare Sales & Marketing Network) -- Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced t... Regenerative Medicine, Neurology, FDA Creative Medical Technology, ImmCelz, stroke
Source: HSMN NewsFeed - May 14, 2021 Category: Pharmaceuticals Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
